Radioactive ray of hope: first test of new drug for deadly eye cancer
Disease control
Recruiting now
This is the first-ever study in people of an experimental radioactive drug called 225Ac-MTI-201. It aims to find the safest dose for patients with metastatic uveal melanoma, a rare and aggressive eye cancer that has spread after other treatments failed. The study will also track …
Phase: PHASE1 • Sponsor: Modulation Therapeutics, Inc. • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC